A functional variant of tandem repeats in human telomerase gene was associated with survival of patients with early stages of non-small cell lung cancer.
OBJECTIVE
Elevated levels of human telomerase (hTERT) mRNA in tumors is a marker for poorer survival in patients with stage I non-small cell lung cancer (NSCLC). A functional variant of MNS16A-short tandem repeats in hTERT (S allele) is associated with higher expression levels of hTERT mRNA compared with the MNS16A-long (L) allele. It is unknown, however, whether or not the hTERT MNS16A variant genotype predicts survival of NSCLC patients.


METHODS
The hTERT genotypes of 808 patients with NSCLC were determined by direct PCR with genomic DNA. Overall median survival times were estimated by the life-table method, and the log-rank test was used to test for homogeneity of the survival curves. Both univariate and multivariate Cox proportional hazards models were used to assess the associations between survival time and the hTERT genotype as well as other known risk factors.


RESULTS
The hTERT variant genotype was not associated with overall survival among the 808 patients. However, among 221 patients with stage I or II NSCLC, the S allele was associated with shorter survival time (P = 0.027, by log-rank test). The adjusted hazard ratios were 1.30 (95% confidence interval, 0.79-2.14; P = 0.310) for the SL-genotype and 2.34 (95% confidence interval, 1.20-4.56, P = 0.012) for the SS-genotype compared with the LL-genotype (P = 0.021 for trend test). These findings were not evident in 587 patients with stage III or IV NSCLC.


CONCLUSIONS
The functional MNS16A-SS genotype may be a marker for poorer survival in early-stage NSCLC.
Wang
Luo
L
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Wang
Li-E
LE
Mao
Li
L
Spitz
Margaret R
MR
Wei
Qingyi
Q
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012333:RNA, Messenger / Q000235:genetics; D015996:Survival Rate; D020080:Tandem Repeat Sequences / Q000235:genetics*; D019098:Telomerase / Q000235:genetics*
D012333:RNA, Messenger; C509186:TERT protein, human; D019098:Telomerase
Cancer Sci. 2006 Dec;97(12):1366-73
17052260
Nature. 2000 Aug 10;406(6796):641-5
10949306
Curr Oncol Rep. 2003 Jul;5(4):318-25
12781075
Nature. 1990 Aug 30;346(6287):866-8
2392154
Chest. 1986 Apr;89(4 Suppl):200S-205S
3514170
Br J Cancer. 2006 May 22;94(10):1452-9
16641908
Nat Med. 1997 Nov;3(11):1271-4
9359704
Chest. 1999 Dec;116(6 Suppl):500S-503S
10619519
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12454-8
10535943
Exp Gerontol. 1992 Jul-Aug;27(4):383-9
1333985
Carcinogenesis. 2009 Jun;30(6):987-90
19369581
Clin Cancer Res. 2002 Sep;8(9):2883-9
12231532
Carcinogenesis. 2009 Aug;30(8):1368-71
19465454
Am J Hum Genet. 2009 Nov;85(5):679-91
19836008
J Natl Cancer Inst. 2001 Aug 15;93(16):1257-63
11504771
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14723-8
9843956
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
J Natl Cancer Inst. 2003 Aug 20;95(16):1211-8
12928346
Dev Genet. 1996;18(2):173-9
8934879
Eur J Cancer. 1997 Apr;33(5):787-91
9282118
Science. 1998 Jan 16;279(5349):349-52
9454332
Nature. 1999 Jul 29;400(6743):464-8
10440377
Blood. 1995 May 1;85(9):2315-20
7727765
Carcinogenesis. 2010 May;31(5):834-41
20061363
Gene. 1999 May 17;232(1):97-106
10333526
Cell. 1991 Nov 15;67(4):645-7
1934066
Oncogene. 2003 Oct 16;22(46):7123-9
14562040
Nat Genet. 2009 Feb;41(2):221-7
19151717
Cell. 1999 Mar 5;96(5):701-12
10089885
Science. 1997 Aug 15;277(5328):955-9
9252327
Neoplasia. 2000 May-Jun;2(3):197-201
10935505
J Natl Cancer Inst. 2000 Nov 1;92(21):1764-72
11058619